argenx to Initiates Second Cohort of P-II Study (ARDA) Results of Empasiprubart for Multifocal Motor Neuropathy
Shots:
- Based on IDMC recommendation, the company plans to initiate a 2nd dose cohort of the P-II study evaluating empasiprubart (ARGX-117) in patients with MMN. The decision was based on the planned interim analysis of 1st dose cohort
- The study focuses to evaluate the safety & efficacy of empasiprubart & to populate a PK/PD model for P-III study dose selection. The results showed a favorable safety & tolerability profile consistent with the P-I study results, after reviewing interim safety data from all patients enrolled in 1st cohort
- Early efficacy signals support proof-of-concept of empasiprubart. Additional EPs incl. time to IVIg retreatment, biomarker analyses of C2 levels, changes in measurements on key clinical efficacy scores & several patient-reported QoL outcome measures
Ref: Globenewswire | Image: argenx
Related News:- argenx Reports the US FDA Acceptance of BLA for Efgartigimod to Treat Generalized Myasthenia Gravis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
